Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Roche Releases Data on 2 Identical Phase 3 Studies of Lebrikizumab for the Treatment of Severe Asthma

Source Link:: http://www.roche.com/media/store/releases/med-cor-2016-02-29.htm

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

RHHBY

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data The first study, LAVOLTA I "met its primary endpoint, showing a significant reduction in the rate of asthma exacerbations in people with higher levels of serum periostin or blood eosinophils, both biomarkers of airway inflammation." This study demonstrated a significant improvement in lung function.

http://www.roche.com...

Clinical Data LAVOLTA II did not meet statistical significance. No new safety signals were observed in either study. The data from both studies will be presented at future medical conferences.

http://www.roche.com...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Feb 29, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Lebrikizumab, Severe Asthma